化合物Tecadenoson T17023

Product Introduction
Bioactivity


英文名: Tecadenoson

描述: Tecadenoson (CVT-510) 是 A1 腺苷受体的选择性激动剂。

体外活性: Tecadenoson is approximately 5 fold more potent to prolong the stimulus-to-His bundle (S-H interval), a measure of slowing AV nodal conduction (EC50=41?nM) than to increase coronary conductance (EC50=200?nM) in the atrial-paced isolated heart. Tecadenoson shortens atrial (EC50=73?nM) but not the ventricular monophasic action potentials (MAP). At concentrations of Tecadenoson (40?nM) and diltiazem (1?μM) that induces equal prolongation of S-H interval (～10?ms), diltiazem, but not Tecadenoson, significantly decreases left ventricular developed pressure (LVP) and markedly increases coronary conductance [1].

体内活性: Intravenous infusions of Tecadenoson and diltiazem causes nearly equal prolongations of P-R interval In atrial-paced anaesthetized guinea-pigs. Tecadenoson (2, 5, 20 μg/kg i.p.) causes a rapid and sustained dose-dependent decrease in NEFA at doses that do not cause bradycardia. Tecadenoson (50 μg/kg) treatment induces a significant bradycardia (50% decrease in heart rate at 25 min) [1][2].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 155 mg/mL (459.49 mM)


关键字: Inhibitor | CVT 510 | P1 receptor | Adenosine Receptor | CVT510 | inhibit | Tecadenoson

相关产品: VPC171 | Doxofylline | A3AR agonist 1 | Fostamatinib | SCH442416 | Piclidenoson | Tozadenant | Istradefylline | Pentostatin | CGS 15943

相关库: Drug Repurposing Compound Library | Neurotransmitter Receptor Compound Library | ReFRAME Related Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Neuronal Signaling Compound Library | Anti-Cancer Clinical Compound Library | GPCR Compound Library | Anti-Cardiovascular Disease Compound Library

化合物Tecadenoson T17023信息由TargetMol中国为您提供，如您想了解更多关于化合物Tecadenoson T17023报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途